Shire PLC’s (SHPG) “Buy” Rating Reaffirmed at Shore Capital
SHPG has been the topic of a number of other research reports. HSBC downgraded shares of Shire PLC from a buy rating to a hold rating in a research report on Monday. Zacks Investment Research upgraded shares of Shire PLC from a hold rating to a buy rating and set a $208.00 target price for the company in a research note on Tuesday, July 5th. Citigroup Inc. reiterated a buy rating on shares of Shire PLC in a research note on Tuesday. Jefferies Group reiterated a buy rating and issued a $262.00 target price on shares of Shire PLC in a research note on Tuesday, September 20th. Finally, Leerink Swann restated a buy rating and set a $213.00 price objective (down from $225.00) on shares of Shire PLC in a research note on Thursday, June 16th. Five equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $230.67.
Shares of Shire PLC (NASDAQ:SHPG) opened at 199.57 on Wednesday. Shire PLC has a one year low of $147.60 and a one year high of $231.32. The stock’s 50 day moving average price is $196.34 and its 200-day moving average price is $185.44. The company has a market cap of $59.44 billion, a PE ratio of 41.47 and a beta of 1.11.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.35. The business had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company’s revenue for the quarter was up 55.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.63 EPS. On average, analysts expect that Shire PLC will post $12.93 EPS for the current year.
The business also recently declared a dividend, which will be paid on Friday, October 7th. Investors of record on Friday, September 9th will be issued a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s dividend payout ratio is presently 15.63%.
A number of large investors have recently added to or reduced their stakes in SHPG. Macquarie Group Ltd. acquired a new stake in Shire PLC during the second quarter worth approximately $5,561,000. Northwestern Mutual Wealth Management Co. increased its stake in Shire PLC by 157.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 8,645 shares of the biopharmaceutical company’s stock worth $1,591,000 after buying an additional 5,293 shares during the period. Cowen Group Inc. acquired a new stake in Shire PLC during the second quarter worth approximately $920,000. Beacon Trust Co. acquired a new stake in Shire PLC during the second quarter worth approximately $2,643,000. Finally, IFP Advisors Inc increased its stake in Shire PLC by 871.9% in the second quarter. IFP Advisors Inc now owns 2,702 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 2,424 shares during the period. 24.26% of the stock is owned by institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.